technetium tc-99m sulfur colloid - Profile

What are the generic drug sources for technetium tc-99m sulfur colloid and what is the scope of patent protection?

Technetium tc-99m sulfur colloid is the generic ingredient in six branded drugs marketed by Ge Healthcare, Mallinckrodt, Sun Pharm Inds Inc, Jubilant, and Bracco, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for technetium tc-99m sulfur colloid

US Patents:	0
Tradenames:	6
Applicants:	5
NDAs:	7

US Patents and Regulatory Information for technetium tc-99m sulfur colloid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ge Healthcare	TECHNETIUM TC 99M SULFUR COLLOID	technetium tc-99m sulfur colloid	SOLUTION;INJECTION, ORAL	017456-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt	TECHNETIUM TC 99M SULFUR COLLOID	technetium tc-99m sulfur colloid	SOLUTION;ORAL	017724-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sun Pharm Inds Inc	AN-SULFUR COLLOID	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017858-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Mallinckrodt	TECHNECOLL	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017059-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ge Healthcare	TECHNETIUM TC 99M TSC	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	017784-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Jubilant	TECHNETIUM TC-99M SULFUR COLLOID KIT	technetium tc-99m sulfur colloid kit	SOLUTION;INJECTION, ORAL	213516-001	Nov 9, 2023	AP	RX	No	No

Summary

Last updated: February 13, 2026

Technetium Tc-99m sulfur colloid (Tc-99m SC) is a widely used radiopharmaceutical for lymphoscintigraphy and hepatic/splenic imaging. Its market size, growth prospects, and competitive landscape are driven by advances in nuclear medicine, regulatory approvals, and healthcare infrastructure. The drug’s fundamental value lies in its established clinical utility, relatively straightforward manufacturing process, and stable regulatory environment. Analyzing its investment scenario involves evaluating manufacturing capacity, regulatory developments, and competitive alternatives.

Market Overview and Demand Drivers

Aspect	Details
Market Size (2022)	Estimated at $400–500M globally for diagnostic imaging agents including Tc-99m sulfur colloid [1].
Growth Rate	Compound annual growth rate (CAGR) projected around 3–5% through 2026, driven by increasing prevalence of cancers, liver, and spleen conditions [2].
Key Applications	Lymphoscintigraphy (sentinel lymph node detection), liver/spleen imaging, reticuloendothelial system (RES) evaluations.
Geographical Distribution	North America and Europe dominate, with China and other APAC regions expanding due to rising healthcare investment.

Market Fundamentals

1. Regulatory Environment

   • Tc-99m sulfur colloid is approved in most markets as a diagnostic agent with established safety and efficacy profiles.
   • Renewed focus on supply security since recent shortages of Mo-99 (parent isotope of Tc-99m) impact availability.
   • No significant patent barriers; most formulations are off-patent, enabling generic competition.
   • Approvals for new delivery methods or formulations can boost usage.

2. Manufacturing and Supply Chain

   • Requires a molybdenum-99 (Mo-99) generator to produce Tc-99m.
   • Supply constraints from aging reactor infrastructure impact availability.
   • Some manufacturers are shifting toward larger, more efficient production facilities.
   • Radiopharmaceuticals have short half-lives (6 hours), demanding robust supply chain logistics.

3. Competitive Landscape

   • Dominated by a few global producers with established facilities, including GE Healthcare, Jubilant DraxImage, and others.
   • Competition from alternative agents such as indium-111 or newer hybrid imaging modalities may influence market share.
   • Generics and biosimilar entry diminishes pricing power.

4. Technological and Clinical Trends

   • Advancements in hybrid imaging (PET/CT, SPECT/CT) limit some traditional tracers but Tc-99m agents retain significant clinical relevance.
   • Innovations in nanoparticles or alternative isotopes may threaten long-term survivability.
   • Growing clinical indications expand the scope of Tc-99m sulfur colloid’s use.

Investment Opportunities and Risks

Opportunities	Risks
Expansion in emerging markets	Supply chain disruptions from Mo-99 shortages
Developing proprietary formulations or delivery methods	Regulatory delays or restrictions
Increasing clinical adoption of hybrid imaging	Competitive pressure from new imaging tech
Potential for manufacturing upgrades	Price erosion due to generic competition

Financial and Strategic Considerations

• Pricing: Stable, with slight decline expected due to patent expirations.
• Market Expansion: Focused on regions with growing healthcare infrastructure and investment.
• R&D Investment: Limited; most innovation is incremental, related to manufacturing or delivery.
• Regulatory Cost: Moderate, with renewal and compliance required for each market.

Key Takeaways

• The Tc-99m sulfur colloid market maintains steady demand with modest growth prospects.
• Supply chain issues, especially regarding Mo-99, pose a tangible risk.
• Manufacturing capacity and regulatory compliance are critical.
• Competitive threats are primarily from estate-developed or alternative imaging agents.
• Long-term growth depends on healthcare infrastructure expansion and integration of hybrid imaging technologies.

FAQs

1. What factors most significantly impact the supply of Tc-99m sulfur colloid?

   • The availability of Mo-99 from aging nuclear reactors and logistical challenges in radiopharmaceutical distribution.

2. How does the aging infrastructure of Mo-99 production affect the market?

   • It causes periodic shortages, prompting market participants to seek alternative production methods or supply chain adjustments.

3. Are there emerging competitors to Tc-99m sulfur colloid in diagnostics?

   • Yes, alternative imaging agents and advances in PET/CT imaging provide competition, but Tc-99m remains predominant in certain indications.

4. What is the outlook for regulatory changes affecting Tc-99m sulfur colloid?

   • Regulatory bodies aim to improve supply security and safety; no major restrictions are expected, but ongoing reviews may impact manufacturing practices.

5. How are innovations in nuclear medicine affecting the long-term viability of Tc-99m radiopharmaceuticals?

   • While innovations are ongoing, Tc-99m’s established clinical profile and infrastructure make it resilient, though competition from new modalities remains a factor.

References

[1] Society of Nuclear Medicine and Molecular Imaging. Market analysis reports (2022).

[2] IQVIA. Global nuclear medicine diagnostics market projections (2022).